title: Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization.
abstract: Four hundred nineteen children and adolescents immunized with live varicella vaccine 4-6 years earlier were enrolled in a study to evaluate the safety and immune response to a booster dose containing approximately 3300 pfu of virus. Of the subjects, 99% (414/419) maintained antibody to varicella zoster virus (VZV) with a geometric mean titer of 25.7 and mean stimulation index (SI) for VZV-specific lymphoproliferation response of 40.3 +/- 5.3 (SE). Some 7-10 days after the booster immunization, seropositivity rates increased to 100% (302/302), and GMT was 143.6 (anamnestic response). At 6 weeks after the booster inoculation, a subset of subjects had 100% seropositivity (74/74) with a GMT of 218.8 and an SI of 58.6. After 3 months, seropositivity was 100% (358/358), GMT was 119.0, and SI was 61.4.
authors.affiliation: Division of Allergy, Immunology, and Infectious Diseases, Joseph Stokes Jr. Research Institute, Children's Hospital of Philadelphia, PA 19104, USA.
authors.forename: B
authors.initials: B
authors.lastname: Watson
authors.forename: E
authors.initials: E
authors.lastname: Rothstein
authors.forename: H
authors.initials: H
authors.lastname: Bernstein
authors.forename: A
authors.initials: A
authors.lastname: Arbeter
authors.forename: A
authors.initials: A
authors.lastname: Arvin
authors.forename: S
authors.initials: S
authors.lastname: Chartrand
authors.forename: D
authors.initials: D
authors.lastname: Clements
authors.forename: M L
authors.initials: ML
authors.lastname: Kumar
authors.forename: K
authors.initials: K
authors.lastname: Reisinger
authors.forename: M
authors.initials: M
authors.lastname: Blatter
mesh_terms: D000293:Adolescent; D000914:Antibodies, Viral / Q000097:blood; D000917:Antibody Formation; D001402:B-Lymphocytes / Q000276:immunology*; D019433:Chickenpox Vaccine; D002648:Child; D002675:Child, Preschool; D005260:Female; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular; D007117:Immunization, Secondary / Q000009:adverse effects; D007223:Infant; D008297:Male; D012449:Safety; D013601:T-Lymphocytes / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology*; D014765:Viral Vaccines / Q000009:adverse effects / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D019433:Chickenpox Vaccine; D014613:Vaccines, Attenuated; D014765:Viral Vaccines